Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)

ClinicalTrials.gov ID: NCT02546700

Public ClinicalTrials.gov record NCT02546700. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 5, 2026, 5:39 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease and a History of Exacerbations

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Phase II, randomized, double-blind, placebo-controlled, parallel-group clinical trial of lebrikizumab in participants with COPD and a history of exacerbations who are treated with inhaled corticosteroid (ICS) and at least one long-acting bronchodilator inhaler medication. This study will be conducted to assess the safety, efficacy, and patient-reported outcome (PRO) measures.

Study identification

NCT ID
NCT02546700
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Hoffmann-La Roche
Industry
Enrollment
309 participants

Conditions and interventions

Eligibility (public fields only)

Age range
40 Years to 80 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 29, 2015
Primary completion
Nov 24, 2016
Completion
Nov 24, 2016
Last update posted
Sep 5, 2017

2015 – 2016

United States locations

U.S. sites
21
U.S. states
14
U.S. cities
20
Facility City State ZIP Site status
Achieve Clinical Research, LLC Birmingham Alabama 35216
Phoenix Medical Research Institute, LLC; Phoenix Medical Research Institute, LLC Peoria Arizona 85381
California Medical Research Associates, Inc. Northridge California 91324
Palmtree Clinical research Inc Palm Springs California 92262
Finlay Medical Research Miami Florida 33126
Progressive Medical Research Port Orange Florida 32127
Columbus Regional Research Institute Columbus Georgia 31904
Southeast Regional Res Group Savannah Georgia 31405
Centex Studies Lake Charles Louisiana 70601
The Clinical Research Ctr St Louis Missouri 63141
Comprehensive Clinical Research Inc. Berlin New Jersey 08009
ISA Clinical Research Jamaica New York 11435
Gastonia Pharmaceutical Research Gastonia North Carolina 28054
Clinical Research Inst. of Southern Oregon, Pc Medford Oregon 97504
Piedmont Research Partners LLC Old Point Station South Carolina 29707
S. Carolina Pharmaceutical Research Spartanburg South Carolina 29303
Baylor College of Medicine; Ben Taub Hospital- Guntupalli Houston Texas 77030
Centex Studies Houston Texas 77062
Western Washington Medical Group Everett Washington 98208
Premier Clinical Research Spokane Washington 99202
MultiCare Health Center of Washington Tacoma Washington 98405

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 45 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02546700, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 5, 2017 · Synced Sep 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02546700 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →